Drugs

, Volume 62, Issue 12, pp 1707–1715

Who Should Receive HMG CoA Reductase Inhibitors?

Current Opinion

Abstract

During the last decade, the development of the HMG CoA reductase inhibitors, commonly referred to as ‘statins’, has contributed greatly to cholesterol lowering therapy and cardiovascular risk reduction. These agents are well tolerated and efficacious. Data on nearly 30 000 patients from five long-term randomised, placebo-controlled trials of statins have clearly demonstrated that a broad range of individuals can benefit from such therapy. These include men or women, younger or older individuals, those with elevated or normal cholesterol levels, with or without myocardial infarction or symptomatic coronary heart disease, with or without hypertension or diabetes mellitus, and those who are smokers or non-smokers. Benefits include reductions in the risks for myocardial infarction, and coronary, cardiovascular and all-cause mortality, stroke and the need for coronary revascularisation. Results of the recently completed Heart Protection Trial have clearly confirmed the results of the earlier trials and support the use of statin therapy in secondary prevention. The role of statins in acute coronary syndromes is being actively evaluated and appears promising. In primary prevention, the data are not as convincing and generalisations cannot be made as to whether, and in which subgroup, drug therapy to lower low density lipoprotein (LDL) cholesterol should be initiated. There are important cost implications to consider and the use of statin therapy has to be judged on an individual basis, particularly in those with high or very high LDL cholesterol levels and/or with multiple risk factors rendering them at high short- and long-term risk of coronary heart disease. There is evidence of a ‘care gap’ in translating trial data into practice, even in secondary prevention, and this needs closing in order to improve patient outcomes.

References

  1. 1.
    Stamler J, Wentworth P, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary disease continuous and graded? JAMA 1986; 256: 2823–8PubMedCrossRefGoogle Scholar
  2. 2.
    Grundy SM. Cholesterol and coronary heart disease: future directions. JAMA 1990; 264: 3053–9PubMedCrossRefGoogle Scholar
  3. 3.
    Lipid Research Clinics Program Investigators. The Lipid Research Clinics coronary primary prevention trials results: I. reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64CrossRefGoogle Scholar
  4. 4.
    Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990; 301: 309–14CrossRefGoogle Scholar
  5. 5.
    Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). Lancet 1994; 344: 1383–9Google Scholar
  6. 6.
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9PubMedCrossRefGoogle Scholar
  7. 7.
    The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57CrossRefGoogle Scholar
  8. 8.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7PubMedCrossRefGoogle Scholar
  9. 9.
    Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22PubMedCrossRefGoogle Scholar
  10. 10.
    The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and lose-dose anticoagulation on obstructive changes in saphenous-vein coronary artery bypass grafts. N Engl J Med 1997; 336: 153–62CrossRefGoogle Scholar
  11. 11.
    Brown BG, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–98PubMedCrossRefGoogle Scholar
  12. 12.
    Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian coronary atherosclerosis intervention trial. Circulation 1994; 89: 959–68PubMedCrossRefGoogle Scholar
  13. 13.
    MAAS Investigators. Effect of simvastatin on coronary atheroma: the multicentre anti-atheroma study (MAAS). Lancet 1994; 344: 633–8CrossRefGoogle Scholar
  14. 14.
    Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997; 80: 278–86PubMedCrossRefGoogle Scholar
  15. 15.
    Teo KK, Burton JR, Buller CE, et al. Long term effects of cholesterol lowering and angiotensin converting enzyme inhibition on coronary atherosclerosis: the simvastatin/enalapril coronary atherosclerosis trial. Circulation 2000; 102: 1748–54PubMedCrossRefGoogle Scholar
  16. 16.
    Burton JR, Tymchak W, Dzavik V, et al., on behalf of the Simvastatin/Enalapril Coronary Atherosclerosis Trial Investigators. Consistent gains by subgroups in retarding progression of coronary atherosclerosis due to long term lipid lowering therapy in normocholesterolemic patients [abstract]. Circulation 2000; 102 Suppl. II: II–706Google Scholar
  17. 17.
    Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo controlled trial. Lancet 2002; 360: 7–22CrossRefGoogle Scholar
  18. 18.
    Sacks FM, Tonkin AM, Shepherd J, et al., for the Prospective Pravastatin Pooling Project Investigators Group. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000; 102: 1893–900PubMedCrossRefGoogle Scholar
  19. 19.
    Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian simvastatin survival study (4S). Circulation 1997; 96: 4211–8PubMedCrossRefGoogle Scholar
  20. 20.
    Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on alchemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998; 81: 333–5PubMedCrossRefGoogle Scholar
  21. 21.
    Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care 1997; 20: 614–20PubMedCrossRefGoogle Scholar
  22. 22.
    Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97: 1436–9PubMedCrossRefGoogle Scholar
  23. 23.
    Schwartz GC, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomised controlled trial. JAMA 2001; 285: 1711–8Google Scholar
  24. 24.
    Sacks FM, Pasternak RC, Gibson CM, et al. Effect of coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet 1994; 344: 1182–6PubMedCrossRefGoogle Scholar
  25. 25.
    Van Mil AHM, Westendorp GJ, Bollen ELE, et al. HMG-CoA reductase inhibitors in the prevention of stroke. Drugs 2000; 59: 1–6PubMedGoogle Scholar
  26. 26.
    Ridker PM. Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-Reactive Protein evaluation. Curr Cardiol Rep 2000; 2: 269–73PubMedCrossRefGoogle Scholar
  27. 27.
    Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. JAMA 1998; 279: 1643–50PubMedCrossRefGoogle Scholar
  28. 28.
    Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172–7PubMedCrossRefGoogle Scholar
  29. 29.
    Brown BG, Zhao XQ, Sacco DE, et al. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781–91PubMedCrossRefGoogle Scholar
  30. 30.
    Schwartz CJ, Valente AJ, Sprague EA, et al. Atherosclerosis: potential targets for stabilization and regression. Circulation 1992; 86 Suppl. III: III 117–23Google Scholar
  31. 31.
    Pearson TA. Lipid-lowering therapy in low-risk patients. Commentary. JAMA 1998; 279: 1659–61CrossRefGoogle Scholar
  32. 32.
    The Expert Panel. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive Summary. National Cholesterol Education Program, National Heart, Lung and Blood Institute, National Institutes of Health. NIH Publication No. 01-3670. May 2001Google Scholar
  33. 33.
    Teo KK, Taylor LK. The care gap: improving delivery of patient care: evidence based cardiovascular medicine [editorial]. Evidence-Based Cardiovasc Med 2000; 4: 82–6CrossRefGoogle Scholar
  34. 34.
    Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in the use of cholesterol-lowering agents in older adults. Arch Intern Med 1998; 158: 1761–8PubMedCrossRefGoogle Scholar
  35. 35.
    Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999; 14: 711–7PubMedCrossRefGoogle Scholar
  36. 36.
    Fonarow GC, Gawlinski A. Rationale and design of the Cardiac Hospitalization Atheroscelrosis Management Program at the University of California Los Angeles. Am J Cardiol 2000; 85: 10A–7APubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Division of CardiologyMcMaster UniversityHamiltonCanada
  2. 2.Division of CardiologyUniversity of AlbertaEdmontonCanada
  3. 3.Rm 3U4, McMaster University Medical CentreHamiltonCanada

Personalised recommendations